RSS

two-drug regimen

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported the positive topline results from the ATLAS Phase III study investigating a novel, long acting injectable two-drug regimen for the treatment of HIV-1. more

News

The US Food and Drug Administration (FDA) has approved the first two-drug regimen for certain patients with human immunodeficiency virus type 1 (HIV-1). more

News